The equity turnaround is structurally positive for solvency perception, but the recurring EPS miss and reliance on repeated note amendments to Streeterville (a known distressed lender) indicate AIM remains in a precarious cash position. Watch for cash runway disclosure in the next 10-Q and for any additional equity raises, which would further dilute the sub-$3M market cap.
Price Chart
Executive Summary
AIM ImmunoTech filed an 8-K reporting a $1.68M debt extension with Streeterville Capital to June 2027, a turnaround from $9.8M deficit to $2.1M equity, and a Q1 EPS miss ($-0.57 vs $ -0.37 consensus). The equity improvement and maturity extension provide near-term liquidity relief, but deep operating losses and a third consecutive note amendment signal ongoing financial distress for this sub-$3M market cap micro-cap.
Key Financial Metrics
Key Facts
- Note maturity extended from June 30, 2026 to June 30, 2027 via Amendment #2 with a $10,000 extension fee
- Outstanding note balance as of May 18, 2026: $1,682,676.16
- Stockholder equity improved to ~$2.1M as of March 31, 2026 from a deficit of ~$9.8M as of Dec 31, 2025, a ~$11.9M swing
- Q1 2026 EPS of $-0.57 missed consensus of $-0.37 by 54.1%
- Revenue not reported — pre-revenue clinical-stage biotech company (pancreatic cancer)
- Original note was $3.3M in Feb 2024; balance has been reduced through repayments to $1.68M
- Company has raised equity-generating funds since March 31, 2026 but amount not disclosed
Financial Impact
Note extension of $1.68M maturing 2027; equity swing of approx $11.9M from deficit to positive; EPS miss of $ -0.20 vs consensus
Risk Factors
- Pre-revenue with deepening operating losses; Q1 EPS miss of -54%
- Third consecutive promissory note extension signals limited financing alternatives
- Market cap of ~$3M makes stock highly sensitive to any news flow or dilution events
- Relies on equity-generating funds (likely ATM offerings) that further dilute shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024353 |
| Exhibit: ex10-1.htm | 0001493152-26-024353 |
| Exhibit: ex99-1.htm | 0001493152-26-024353 |
| Document: 0001493152-26-024353-index-headers.html | 0001493152-26-024353 |
| Document: 0001493152-26-024353-index.html | 0001493152-26-024353 |
| Document: 0001493152-26-024353.txt | 0001493152-26-024353 |
| 8-K Data (Synthetic) | 0001493152-26-024353 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers